Pharmafile Logo

psoriasis

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

Body image and mental health: The psoriasis connection

As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...

Mednet Group

- PMLiVE

European approval for Skyrizi, hot on the heels of US

Welcome news, but can't replace $20bn Humira

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

- PMLiVE

Almirall acquires Allergan’s dermatology portfolio for $650m

The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links